Back to Search
Start Over
Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII)
- Source :
- The Patient
- Publication Year :
- 2019
-
Abstract
- Introduction Prophylactic treatment of severe hemophilia A is burdensome, requiring frequent intravenous injections. Extended half-life (EHL) factor VIII replacement therapies offer longer intervals between infusions while still meeting efficacy and safety outcomes; however, patient perspectives following long-term use of such products in the real-world remain unknown. Objective We aimed to explore the importance of infusion frequency and the potential benefits of reduced infusion frequency among patients receiving prophylactic treatment with an EHL product (BAY 94-9027). Methods Patients with severe hemophilia A participating in the PROTECT VIII extension study were invited to participate in a semi-structured, concept elicitation ‘exit’ interview to discuss their experiences. Participants were recruited from Israel, The Netherlands, and the US. Interview transcripts were translated into English and analyzed using thematic analysis methods. Results Sixteen participants (29–68 years of age) infusing with BAY 94-9027 once every 7 days, once every 5 days, or twice weekly were interviewed. Participants reported infusion frequency (alongside efficacy) as the most important treatment attribute influencing their satisfaction with therapy. Patient-reported benefits of reduced infusion frequency and longer duration of factor coverage included greater ability to participate in physical activities; better vein health; less time to schedule and administer factor VIII; reduced impact on work; and improved emotional well-being. Conclusions This study provides rich insights into the experiences of patients with EHL products and the value of reduced infusion frequency. Such data could be of value to a range of stakeholders (e.g. regulators, payers) and facilitate patient–clinician discussions to promote tailored treatment decisions.
- Subjects :
- Adult
Male
medicine.medical_specialty
Time Factors
MEDLINE
Hemophilia A
Health administration
Interviews as Topic
Medicine
Humans
Original Research Article
Patient participation
Infusions, Intravenous
Qualitative Research
Aged
Netherlands
Health economics
Factor VIII
business.industry
Coagulants
Public health
Middle Aged
Tailored treatment
Physical therapy
Thematic analysis
Patient Participation
business
Qualitative research
Subjects
Details
- ISSN :
- 11781661
- Volume :
- 12
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- The patient
- Accession number :
- edsair.doi.dedup.....fa572e75980621da298743a78170e67d